·¬ΗΡΙηΗψapp

Meeting Coverage

ASCO

American Society of Clinical Oncology

TTFields Therapy Yields OS Improvement in Second-Line NSCLC

However, device was not tested alongside current standard of care, expert points out

ASCO over a photo of McCormick place in Chicago, IL.

Latest ASCO Meeting Coverage

Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer

No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost

June 7, 2023
Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission

PET-negative patients after chemoimmunotherapy fared well with observation alone

June 7, 2023
FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer

Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says

June 7, 2023
Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC

"Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert

June 7, 2023
Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years

Retrospective study finds no difference in OS between patients who stop and those who continue

June 6, 2023
No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC

The strategy also led to increased toxicity

June 6, 2023
New Data in NSCLC Bolster Support for Perioperative Immunotherapy

EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator

June 5, 2023
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma

The CAR T-cell therapy led to significantly longer overall survival

June 5, 2023
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials

High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents

June 5, 2023
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma

Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets

June 5, 2023
T-DXd Proves Mettle in Multiple Solid Tumors

Data from ongoing DPT02 trial show broad activity in HER2-expressing advanced disease

June 5, 2023
Omitting RT Safe in Many Locally Advanced Rectal Cancers

Most intermediate-risk cases can be cured without pelvic radiation, says investigator

June 5, 2023
Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma

INDIGO data demonstrate that some patients can delay "toxic" chemo and radiation, says expert

June 4, 2023
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma

SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease

June 4, 2023

Videos